Aligos Therapeutics presented positive Phase 1 data for its lead hepatitis B virus candidate, pevifoscorvir sodium, at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. The poster session, titled "High Viral Suppression in Chronic HBV Infection," took place on February 23, 2026, during the conference that ran from February 22 to 25.
The data demonstrated high viral suppression in patients with chronic HBV infection, providing the first clinical evidence that pevifoscorvir can achieve the viral reductions needed to advance to the pivotal B‑SUPREME Phase 2 study. Dr. Stanley Wang, MD, presented the findings in the poster session.
Aligos has concentrated its remaining resources on pevifoscorvir after cutting other programs. The company faces significant financial challenges, including negative margins and declining revenue, making the positive clinical data a critical milestone for its future prospects.
In addition to the HBV presentation, Aligos shared data on ALG‑097558, a coronavirus protease inhibitor, in patients with hepatic and renal impairment. The results underscore the company’s ongoing efforts to advance its COVID‑19 program, which is supported by federal funding.
Chairman, President, and CEO Lawrence Blatt said, "We are pleased to continue showcasing the best/first‑in‑class pevifoscorvir sodium data from the Phase 1 study in participants with chronic HBV infection. Additionally, we continue to move our COVID program forward with grants from government agencies and are pleased to show some of this important clinical work at CROI this year."
The Phase 1 results strengthen Aligos’ position as a potential best‑in‑class capsid assembly modulator and provide a foundation for the upcoming B‑SUPREME Phase 2 study. The company’s focus on a single, high‑potential candidate, coupled with federal support for its COVID program, positions it to navigate its financial challenges while pursuing a potentially transformative therapy for chronic HBV.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.